Nuvilex, Inc. (OTCQB: NVLX) saw its share volume cut in half on May 27th with 3,853,590 shares exchanging hands compared to its three month daily average volume of 8,024,321 shares.
Nuvilex recently announced together with Translational Drug Development (TD2) in Scottsdale, Arizona, preparations have begun for US-based preclinical and then clinical studies on the unbearable pain and the accumulation of fluid in the abdominal cavity which are two commonly occurring symptoms associated with advanced pancreatic cancer.
Kenneth L. Waggoner, CEO and President of Nuvilex stated, "TD2, arguably the most reputable CRO in the US that specializes in oncology, has committed to undertake these important studies on the development of severe, untreatable pain and the accumulation of ascites fluid. These are the two major symptoms associated with advanced pancreatic cancer. If successful, these studies will show that our pancreatic cancer treatment can play a significant role in improving the quality of life of patients suffering from this dreadful disease." Waggoner continued, "We are now engaged in a 'two-pronged attack' on pancreatic cancer with studies by TD2 and the Australian Phase 2b clinical trial, first by attempting to improve patients' quality of life and second by attempting to increase the life span of patients with advanced pancreatic cancer."
NVLX closed the day at $.255 on May 27th, 4.53% lower than its previous close of $.2671.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
Advanced Cell Technology Sees Share Volume Remain Strong
Advanced Cell Technology, Inc. (OTCQB: ACTC) saw its share volume remain strong on May 27th with 11,253,063 shares exchanging hands, right on par with its three month daily average volume of 11,172,135 shares.
Just last month, ACTC announced that the company's Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 TIME 100 annual list of the hundred most influential people in the world.
Advanced Cell Technology is a biotechnology company developing cellular therapies for treating diseases that impact millions of people worldwide. Helmed by Chairman and CEO Gary Rabin, ACTC is currently conducting the only human embryonic stem cell (hESC)-based clinical trials: two Phase I/II trials in the US and one in Europe. Initial results from the two US trials were published earlier this year in The Lancet. ACTC is also focused on its Hemangioblast platform for treating blood and cardiovascular diseases, and its mesenchymal stem cell program. ACTC’s patented "embryo-safe" technique for deriving hESCs without harming embryos was documented in Nature.
ACTC closed the day at $.0615 on May 27th, up 3.36% from its previous close of $.0595.
OncoSec Medical To Present At Four Events June
OncoSec Medical Inc. (OTCQB: ONCS) saw its share volume dip on May 27th with 1,077,805 shares exchanging hands, significantly lower than its three month daily average volume of 2,733,027 shares.
OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at four events in June.
- Punit Dhillon, President and CEO, will take part in a panel discussion titled, “Alternative Business Models in Biotech”, at the Boston Biotech Boston CEO Conference on June 5, 2014.
- Robert Pierce, M.D., Chief Medical Officer, will present a corporate overview of the company at the LD Micro 4th Invitational Conference, on June 4, 2014.
- Robert Pierce, M.D., Chief Medical Officer, will present an overview of the company at the 2014 BIO International Convention, as part of the BIO Business Forum, taking place June 23-26 at the San Diego Convention Center in San Diego, California.
- OncoSec representatives will attend and present at the 4th European Post-Chicago Melanoma/Skin Cancer Meeting, hosted by the European Association of Dermato Oncology (EADO).
ONCS closed the day at $.75 on May 27th.
Abbatis Bioceuticals Cancels Financing
Abbatis Bioceuticals Corp. (OTCPINK: ATTBF) saw its share volume slide on May 27th with 662,169 shares exchanging hands, much lower than its three month daily average volume of 1,116,690 shares.
This comes after the company recently announced that it is cancelling its proposed dilutive non-brokered private placement for the issuance of up to 2 million units at a price of one dollar per unit originally announced on April 23rd, 2014. This financing is being cancelled due to current fluctuating market prices and the Company's lack of immediate need for funds.
With no other recent news, here is what is known about the company:
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market.
ATTBF closed the day at $.761 on May 27th, 9.86% higher than its previous close of $.6927.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.